Taken together, our research supports the oncogenic role of G6PD in human tumorigenesis, unveils new mechanisms underlying RCC carcinogenesis, and points to strategies of designing innovative therapeutic agents to improve RCC treatment. This evidence concerns the gene G6PD and renal cell carcinoma.